Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% Gross Margin % is 0.00% as of Sep. 2025. The stock has 2 warning signs investors should review. Among 734 Biotechnology companies, Windtree Therapeutics ranks worse than 136239.65% on this metric.
WINT's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.905 * Ranked among companies with meaningful Gross Margin % only.
Windtree Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Windtree Therapeutics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Windtree Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Windtree Therapeutics Gross Margin % Related Terms
Windtree Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WINT vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Windtree Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Windtree Therapeutics (WINT) has a Gross Margin % of 0.00% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Windtree Therapeutics and its competitors. Over the past decade, Windtree Therapeutics' Gross Margin % has ranged from 5.88 to 5.88. According to the industry distribution chart, Windtree Therapeutics ranks #999999 out of 734 companies in the Biotechnology industry.
Is Windtree Therapeutics' Gross Margin % too high?
Windtree Therapeutics' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 5.88 to a high of 5.88. Based on the distribution chart, Windtree Therapeutics ranks #999999 out of 734 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Windtree Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #999999 out of 734 companies for Gross Margin %. This places Windtree Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Windtree Therapeutics' own Gross Margin % has ranged from 5.88 to 5.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Windtree Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Gross Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
